spironolactone has been researched along with Cerebral Infarction in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)." | 5.31 | Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001) |
| "Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)." | 1.31 | Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z | 1 |
| Luo, X | 1 |
| Liu, M | 1 |
| Jiang, J | 1 |
| Li, Y | 1 |
| Huang, Z | 1 |
| Wang, L | 1 |
| Cao, J | 1 |
| He, L | 1 |
| Huang, S | 1 |
| Hu, H | 1 |
| Li, L | 1 |
| Chen, L | 1 |
| Oyamada, N | 1 |
| Sone, M | 1 |
| Miyashita, K | 1 |
| Park, K | 1 |
| Taura, D | 1 |
| Inuzuka, M | 1 |
| Sonoyama, T | 1 |
| Tsujimoto, H | 1 |
| Fukunaga, Y | 1 |
| Tamura, N | 1 |
| Itoh, H | 1 |
| Nakao, K | 1 |
| Dorrance, AM | 1 |
| Osborn, HL | 1 |
| Grekin, R | 1 |
| Webb, RC | 1 |
| Guibert, F | 1 |
| Laporte, A | 1 |
| Bidabe, AM | 1 |
| Henry, P | 1 |
| Caille, JM | 1 |
1 trial available for spironolactone and Cerebral Infarction
| Article | Year |
|---|---|
Treatment of cerebral infarcts with anti-oedema agents.
Topics: Adrenocorticotropic Hormone; Aged; Brain Edema; Cerebral Infarction; Cosyntropin; Glycerol; Humans; | 1979 |
3 other studies available for spironolactone and Cerebral Infarction
| Article | Year |
|---|---|
Elabela-apelin-12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1-P2X7 signaling pathway.
Topics: Animals; Apelin; Apelin Receptors; Cerebral Infarction; Peptide Hormones; Platelet Aggregation; Sign | 2023 |
The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia.
Topics: Angiogenic Proteins; Animals; Apoptosis; Blood Pressure; Brain; Cerebral Infarction; Drug Evaluation | 2008 |
Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats.
Topics: Aldosterone; Animals; Aorta; Basal Ganglia; Blood Pressure; Body Weight; Cerebral Cortex; Cerebral I | 2001 |